CDX‐2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases
- 15 September 2006
- journal article
- Published by Wiley in Histopathology
- Vol. 49 (4) , 381-387
Abstract
Aims: CDX‐2 is a highly sensitive and specific marker of intestinal epithelial cells and their neoplastic counterparts. CDX‐2 status in pseudomyxoma peritonei (PMP) has been barely reported. The aim of this study was to investigate the clinicopathological features of 42 cases of PMP with a special emphasis on CDX‐2.Methods and results: All patients were treated by cytoreduction. Immunohistochemistry was performed for CDX‐2, MUC‐2, MUC‐5AC, cytokeratin (CK) 7 and CK20. Statistical correlation was evaluated for age, sex, completeness of cytoreduction and histological subtype with overall and progression‐free survival (OS and PFS). PMP consisted of 32 cases of disseminated peritoneal adenomucinosis and 10 cases of peritoneal mucinous carcinomatosis. The appendix evaluated in 25 cases showed two mucinous adenocarcinomas and 21 low‐grade appendiceal mucinous neoplasms. CDX‐2 was diffusely positive in 40 cases, with the remaining two cases being focally positive. All cases demonstrated diffuse reactions to CK20 and MUC‐2, and variable reactions to MUC‐5AC, while CK7 was variably positive in 38 cases. Five‐year OS was 97%. Histological type was significantly correlated with PFS (P = 0.02).Conclusions: CDX‐2 is diffusely and strongly positive in PMP. This is a useful marker to confirm an appendiceal origin of PMP, particularly when used in conjunction with CK7, CK20, MUC‐2 and MUC‐5AC.Keywords
This publication has 35 references indexed in Scilit:
- The Usefulness of CDX-2 for Differentiating Primary and Metastatic Ovarian Carcinoma: An Immunohistochemical Study Using a Tissue MicroarrayJournal of Korean Medical Science, 2005
- Immunohistochemical Characterization of Signet-Ring Cell Carcinomas of the Stomach, Breast, and ColonAmerican Journal of Clinical Pathology, 2004
- Immunohistochemical Characterization of Signet-Ring Cell Carcinomas of the Stomach, Breast, and ColonAmerican Journal of Clinical Pathology, 2004
- The Value of Cdx2 Immunostaining in Differentiating Primary Ovarian Carcinomas From Colonic Carcinomas Metastatic to the OvariesInternational Journal of Gynecological Pathology, 2004
- Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusionJournal of Surgical Oncology, 2003
- MUC2 Is a Molecular Marker for Pseudomyxoma PeritoneiLaboratory Investigation, 2002
- The MUC family: an obituaryTrends in Biochemical Sciences, 2002
- Cloning and chromosome assignment of the human CDX2 geneAnnals of Human Genetics, 1997
- Mucinous Ovarian Tumors With Pseudomyxoma PeritoneiInternational Journal of Gynecological Pathology, 1992
- Pseudomyxoma peritonei from metastatic colloid carcinoma of the breastGastrointestinal Radiology, 1991